CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) – Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company developing a strong pipeline of oncology and neuroscience product candidates designed to uniquely disrupt the dynamics of cell signaling, announced today the closing of its initial public offering of 8,625,000 Class A common shares, including the full exercise by the underwriters of their over-allotment option to purchase 1,125,000 common shares of Class A, at a public offering price of $ 15.00 per share, for total gross proceeds of approximately $ 129.4 million, before the deduction of underwriting discounts and commissions and estimated offering costs payable by Immuneering.
Immuneering’s Class A common shares began trading on the Nasdaq Global Market under the symbol “IMRX” on July 30, 2021.
Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as co-managers of the books.
A registration statement relating to the securities sold under the Offer was declared effective by the United States Securities and Exchange Commission on July 29, 2021. This offer is being made only by way of a prospectus. Copies of the final prospectus relating to this offering can be obtained, when available, by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus @ morganstanley .com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at (877) 821-7388 or by email at prospectus—[email protected]; or Cowen and Company, LLC, c / o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by phone at 833-297-2926.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be. illegal before registration or qualification under the securities laws of that state or jurisdiction.
About Immuneering Corporation
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes in a range of debilitating oncologic and neurologic diseases by applying its in-depth knowledge of translational bioinformatics at every stage of the drug development process. Immuneering has over a decade of experience in translational bioinformatics and in generating information on the mechanisms of drug action and responses to treatment of patients. Building on this experience, Immuneering has developed a disease-independent platform that enables the company to use human data, novel biology and chemistry, and translational planning to create and advance its proprietary pipeline. exclusive. Immuneering’s current development programs in oncology focus on providing potential treatments for patients with solid tumors caused by mutations in oncological signaling pathways, including the MAPK pathway. Immuneering’s flagship product candidate, IMM-1-104, is designed to be a highly selective dual MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients with RAS mutant tumors. In addition, Immuneering has six other discovery-stage oncology programs that are designed to target the MAPK or mTOR pathway, and two discovery-stage neuroscience programs.
This press release includes certain disclosures that contain “forward-looking statements” including, without limitation, statements regarding Immuneering’s intended use of the net proceeds of the offering. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions which are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in drug development in oncology and neuroscience, including target discovery, target validation, lead compound identification , optimization of flagship compounds, preclinical studies and clinical trials. These and other risks and uncertainties are further described in the section entitled “Risk Factors” of the final prospectus relating to the offering filed with the United States Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Immuneering assumes no obligation to update such information, except as required by applicable law.
Contact Person: Rebecca Kusko, Ph.D. Immuneering Corporation 617-500-8080 [email protected]
Investor contact: Anne Marie Fields Managing Director Rx Communications [email protected]
Copyright 2021 GlobeNewswire, Inc.